HOLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Hologic Inc (HOLX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the technical indicators show bullish momentum, the overbought RSI and negative short-term stock trend probabilities suggest caution. Additionally, the company's latest financial performance shows declining net income and EPS, which could indicate challenges in profitability. The lack of strong AI or SwingMax trading signals further supports a hold recommendation.
The stock shows bullish momentum with MACD positive and expanding, and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). However, RSI at 81.537 indicates the stock is overbought. Key resistance levels are at 75.68 and 75.829, with support at 75.199 and 75.05.
Hedge funds have significantly increased their buying activity by 4616.24% over the last quarter. Additionally, RadNet's acquisition of Gleamer and strong Q4 revenue could indirectly benefit the sector.
Insiders are neutral with no significant activity. Analysts have downgraded the stock, and the price target has been reduced. The stock also has an 80% chance of declining in the short term (-5.41% next day, -8.75% next week).
In Q1 2026, revenue increased by 2.54% YoY to $1.048 billion, and gross margin improved to 57.21%. However, net income dropped by -10.90% YoY to $179.1 million, and EPS fell by -9.20% YoY to 0.79, indicating declining profitability.
Evercore ISI downgraded Hologic to In Line from Outperform, with a reduced price target of $78 (down from $79), reflecting a neutral to slightly bearish sentiment among analysts.
